Search

Author/Creator She, Dewei

1. A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Issue 3 (June 2018)

Authors:
Baverel, Paul; She, Dewei; Piper, Edward; Ueda, Shinya; Yoshioka, Tomoko; Faggioni, Raffaella; Gevorkyan, Hakop
Journal:
Drug metabolism and pharmacokinetics
Issue:
Volume 33:Issue 3(2018)
Page Start:
150
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Issue 3 (May 2021)

Authors:
Marignier, Romain; Bennett, Jeffrey L.; Kim, Ho Jin; Weinshenker, Brian G.; Pittock, Sean J.; Wingerchuk, Dean; Fujihara, Kazuko; Paul, Friedemann; Cutter, Gary R.; Green, Ari J.; Aktas, Orhan; Hartung, Hans-Peter; Lublin, Fred D.; Williams, Ian M.; Drappa, Jorn; She, Dewei; Cimbora, Daniel; Rees...
Journal:
Neurology
Issue:
Volume 8:Issue 3(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Issue 9 (September 2015)

Authors:
Brightling, Christopher E; Chanez, Pascal; Leigh, Richard; O'Byrne, Paul M; Korn, Stephanie; She, Dewei; May, Richard D; Streicher, Katie; Ranade, Koustubh; Piper, Edward
Journal:
Lancet
Issue:
Volume 3:Issue 9(2015)
Page Start:
692
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Issue 9 (September 2015)

Authors:
Brightling, Christopher E; Chanez, Pascal; Leigh, Richard; O'Byrne, Paul M; Korn, Stephanie; She, Dewei; May, Richard D; Streicher, Katie; Ranade, Koustubh; Piper, Edward
Journal:
Lancet
Issue:
Volume 3:Issue 9(2015)
Page Start:
692
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Issue 10206 (12th October 2019)

Authors:
Cree, Bruce A C; Bennett, Jeffrey L; Kim, Ho Jin; Weinshenker, Brian G; Pittock, Sean J; Wingerchuk, Dean M; Fujihara, Kazuo; Paul, Friedemann; Cutter, Gary R; Marignier, Romain; Green, Ari J; Aktas, Orhan; Hartung, Hans-Peter; Lublin, Fred D; Drappa, Jorn; Barron, Gerard; Madani, Soraya; Ratchfo...
Journal:
Lancet
Issue:
Volume 394:Issue 10206(2019)
Page Start:
1352
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. (May 2022)

Authors:
Rensel, Mary; Zabeti, Aram; Mealy, Maureen A; Cimbora, Daniel; She, Dewei; Drappa, Jorn; Katz, Eliezer
Journal:
Multiple sclerosis
Issue:
Volume 28:Number 6(2022)
Page Start:
925
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design. Issue 3 (25th January 2021)

Authors:
Bonaca, Marc P; George, Richard T; Morrow, David A; Bergmark, Brian A; Park, Jeong-Gun; Abuhatzira, Liron; Vavere, Andrea L; Karathanasis, Sotirios K; Jin, ChaoYu; She, Dewei; Hirshberg, Boaz; Hsia, Judy; Sabatine, Marc S
Journal:
European heart journal
Issue:
Volume 8:Issue 3(2022)
Page Start:
243
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. (November 2021)

Authors:
Cree, Bruce AC; Bennett, Jeffrey L; Kim, Ho Jin; Weinshenker, Brian G; Pittock, Sean J; Wingerchuk, Dean; Fujihara, Kazuo; Paul, Friedemann; Cutter, Gary R; Marignier, Romain; Green, Ari J; Aktas, Orhan; Hartung, Hans-Peter; Williams, Ian M; Drappa, Jorn; She, Dewei; Cimbora, Daniel; Rees, Willia...
Journal:
Multiple sclerosis
Issue:
Volume 27:Number 13(2021)
Page Start:
2052
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗